Cover Image
市場調查報告書

類風濕性關節炎的全球市場分析 (2016年)

Global Rheumatoid Arthritis Market Report: 2016 Edition

出版商 Koncept Analytics 商品編碼 362961
出版日期 內容資訊 英文
訂單完成後即時交付
價格
Back to Top
類風濕性關節炎的全球市場分析 (2016年) Global Rheumatoid Arthritis Market Report: 2016 Edition
出版日期: 2016年07月05日 內容資訊: 英文
簡介

本報告提供全球類風濕性關節炎的相關市場相關分析,類風濕性關節炎概要,及全球市場實際成果值、預測值,各藥物種類、各級的市場佔有率,美國市場詳細趨勢,主要的推動及阻礙市場要素,企業間市場佔有率,主要企業簡介等的調查評估。

第1章 市場概要

  • 所謂關節炎
  • 關節炎的種類
  • 類風濕性關節炎
  • 病因
  • 病期
  • 診斷
  • 治療選擇

第2章 全球市場

  • 全球類風濕性關節炎市場 (以金額為準)
  • 全球類風濕性關節炎市場:各類藥物
  • 全球類風濕性關節炎的市場佔有率:各藥物
  • 全球類風濕性關節炎的市場佔有率:生技藥品的情況

第3章 美國市場

  • 美國的類風濕性關節炎市場 (以金額為準)
  • 美國的類風濕性關節炎的患者數、盛行率
  • 美國的類風濕性關節炎的盛行率的變化
  • 美國的類風濕性關節炎市場:抗TNF (腫瘤壞死因子) 製劑的利用人口
  • 美國的類風濕性關節炎市場:生技藥品的利用人口

第4章 市場動態

  • 主要趨勢
  • 市場成長的推動要素
  • 課題

第5章 競爭環境

  • 全球市場
  • 美國市場

第6章 企業簡介

  • AbbVie
    • 產業概要
    • 主要的財務指標
    • 產業策略
  • Johnson & Johnson
  • Amgen Inc.
  • Pfizer Inc.

圖表一覽

目錄

Arthritis means inflammation in a joint. Inflammation is a normal immune response in a body. It happens when the body, no longer has the ability to turn off the inflammatory response and thereby start damaging the healthy tissues of the body. This inflammation causes redness, warmth, swelling, and pain within the joint. There are more than 100 different types of arthritis, with different causes and treatment methods. Major classification of arthritis includes degenerative arthritis, inflammation arthritis, infectious and metabolic arthritis.

Rheumatoid arthritis or RA is classified under inflammatory arthritis. It is a chronic autoimmune disease. About 1 out of every 5 people who suffer from rheumatoid arthritis get lumps on their skin called rheumatoid nodules. This disease occurs in 4 main stages and can be diagnosed with certain blood tests, medical history, and imaging tests. There is no cure for rheumatoid arthritis, but there are various treatments available that reduce the pain like drugs, physical exercise or surgery.

The rheumatoid arthritis market is expected to grow in the coming years with growing demand for better medical facilities and more effective drugs. The US rheumatoid arthritis market dominates the global market with larger number of rheumatoid arthritis patients. The key trends of the market include increasing competition from anti-IL6 drugs, rising FDA approvals to RA drugs, use of complementary and alternative medicines, and increasing share of biosimilars.

The key factors driving the growth of the RA market includes increasing women population, escalating global ageing population, rising health care expenditure, rising cigarette consumption, and increasing obese population. However, there are certain factors which hinder the growth of the rheumatoid arthritis market like high cost of treatment and high research and development cost.

The report offers an in-depth analysis of the “Global Rheumatoid Arthritis Market” segmented into global and regional market. Competition is concentrated in the hands of few major pharmaceutical companies. Major RA companies that have been covered in the report include AbbVie, JNJ, Amgen Inc. and Pfizer Inc.

Table of Contents

1. Market Overview

  • 1.1. Arthritis
  • 1.2. Types of Arthritis
  • 1.2. Rheumatoid Arthritis
  • 1.3. Causes
  • 1.4. Stage
  • 1.5. Diagnosis
  • 1.6. Treatment Options

2. Global Market

  • 2.1. Global Rheumatoid Arthritis Market by Value
  • 2.2. Global Rheumatoid Arthritis Market by Drug Class
  • 2.3. Global Rheumatoid Market Share by Drug
  • 2.4. Global Rheumatoid Arthritis Market Share by Biologics

3. The U.S. Market

  • 3.1. The US Rheumatoid Arthritis Market by Value
  • 3.2. The US Rheumatoid Arthritis Patient Prevalence
  • 3.3. The US Rheumatoid Arthritis Patient Penetration
  • 3.4. The US Rheumatoid Arthritis Anti-TNF Population
  • 3.5. The US Rheumatoid Arthritis Biologics Population

4. Market Dynamics

  • 4.1. Key Trends
    • 4.1.1. Increasing Competition from Anti-IL-6 Drugs
    • 4.1.2. Rising FDA Approvals to Rheumatoid Arthritis Drugs
    • 4.1.3. Auto-Injectors for Rheumatoid Arthritis
    • 4.1.4. Use of Complementary and Alternative Medicines (CAMs)
    • 4.1.5. Increasing Biosimilars for Rheumatoid Arthritis
  • 4.2. Growth Drivers
    • 4.2.1. Increasing Female Population Worldwide
    • 4.2.2. Escalating Global Ageing Population
    • 4.2.3. Rising Global Health Care Expenditure
    • 4.2.4. Rising Cigarette Consumption
    • 4.2.5. Increasing Obese Population
  • 4.3. Challenges
    • 4.3.1. High Cost of Treatment
    • 4.3.3. High R&D Cost

5. Competitive Landscape

  • 5.1. Global Market
    • 5.1.1. Rheumatoid Arthritis Market Share by Company
    • 5.1.2. Rheumatoid Arthritis Market Competition by Anti-TNF
    • 5.1.3. Rheumatoid Arthritis Competition by Biologics
  • 5.2. The US Market
    • 5.2.1. Rheumatoid Arthritis Brand (Company) Share

6. Company Profiles

  • 6.1. AbbVie
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. Johnson & Johnson
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. Amgen Inc.
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. Pfizer Inc.
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies

List of Charts

  • Types of Arthritis
  • Global Rheumatoid Arthritis Market by Value (2015-2020E)
  • Global Rheumatoid Arthritis Market by Drug Class (2015/2020E)
  • Global Rheumatoid Arthritis Market Share by Drug (2016E)
  • Global Rheumatoid Arthritis Market Share by Biologics (2015)
  • The US Rheumatoid Arthritis Market by Value (2015-2020E)
  • The US Rheumatoid Arthritis Patient Prevalence (2015-2020E)
  • The US Rheumatoid Arthritis Patient Penetration Rate (2015-2020E)
  • The US Rheumatoid Arthritis Anti-TNF Population (2015-2020E)
  • The US Rheumatoid Arthritis Biologics Population (2015-2020E)
  • Global Female Population (2010-2015)
  • Increasing Global Ageing Population of 60 Years or Older (2000-2030E)
  • Global Healthcare Expenditure (2009-2015E)
  • Increasing Cigarette Consumption (1910-2014)
  • Increasing Obese Population (2010-2015E)
  • Rheumatoid Arthritis Drug Prices (2013-2016E)
  • Rheumatoid Arthritis Market Share by Company (2015/2020E)
  • The US Rheumatoid Arthritis Brand (Company) Share (2016E)
  • Abbvie Revenue Share by Pharmaceutical Products (2015)
  • Abbvie Revenue Share by Region (2015)
  • Abbvie Revenue and Net Income (2012-2015)
  • Abbvie Research and Development Expenditure (2015)
  • Johnson & Johnson Revenue by Segment (2015)
  • Johnson & Johnson Revenue and Net Income (2012-2015)
  • Amgen Revenue Share by Products (2015)
  • Amgen Revenue and Net Income (2012-2015)
  • Pfizer Inc. Revenue by Segment (2015)
  • Pfizer Inc. Revenue and Net Income (2012-2015)

List of Tables

  • Development Progress of Anti-IL-6 Drugs for RA (2015)
  • Rheumatoid Arthritis Drug Approval and Developments (2015)
  • Use of Complementary and Alternative Medicines (2015)
  • Clinical Development of Biosimilars in Rheumatoid Arthritis (2015)
  • Global Rheumatoid Arthritis Competition by Biologics (2015)
  • New Products of Pfizer with FDA Approval (2015/2016)
  • New Innovative Product Portfolio of Johnson & Johnson (2015)
  • New Products of Pfizer with FDA Approval (2015/2016)
Back to Top